Login to Your Account



YM Funding Gets Up To C$23M For Tesmilifene Phase III Trials

By Karen Pihl-Carey


Wednesday, September 15, 2004
As its Phase III tesmilifene trial continues to enroll breast cancer patients, YM BioSciences Inc. entered a bought-deal agreement that could result in gross proceeds for the company of C$23 million (US$17.8 million). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription